The diagnostics technology developer has added a $36m investment co-led by Khosla Ventures and Redmile Group to a $44m BioMed Realty-backed round closed last year.

Existing investors Medtronic and Johnson & Johnson were reportedly among 10 backers in the sleep apnea therapy developer's latest round.

Pharmaceutical company Chiesi Group's strategic investment unit has become an investor in Glycomine, which develops replacement therapies for rare diseases.

The $8m final tranche of the round, which was co-led by Baxalta Ventures, was triggered this week when Syntimmune chose the dose for its lead candidate'sphase 1b/2a trials.

Stanford University-funded accelerator StartX was an investor in the round, which was co-led by Mayfield and Norwest Venture Partners.

Global Sources and existing backers Swisscom and ZKB were among the investors in the fertility tracking wristband maker's latest round, which has been closed at $9.7m.

Biotechnology developer Magenta Therapeutics, which exploits Harvard research, has launched with series A funding provided by investors including Alphabet.

Nereus Pharmaceuticals is set to record an exit from BeyondSpring, which is targeting $100m in its initial public offering.